Scientists have developed a potentially transformative new technique that could aid in the discovery and development of new therapeutics for a number of globally prevalent autoimmune diseases.
Adjuvant Osimertinib as a Standard Therapy for EGFR-Positive NSCLC
Treatment with osimertinib (Tagrisso) after surgery significantly reduced the risk of death in adults with completely resected EGFR-positive stage IB, II, or IIIA non-small cell
July 7, 2023